Opportunities and challenges following approval of resmetirom for MASH liver disease

Opportunities and challenges following approval of resmetirom for MASH liver disease

The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature medicine 2024-12, Vol.30 (12), p.3402-3405
Hauptverfasser: Lazarus, Jeffrey V., Ivancovsky Wajcman, Dana, Mark, Henry E., Younossi, Zobair M., Kopka, Christopher J., Cohen, Nevin, Bansal, Meena B., Betel, Michael, Brennan, Paul N.
Format: Artikel
Sprache:eng
Schlagworte:
692/699/1503/1607/2750
692/699/1503/1607/2751
692/700/1538
692/700/155
692/700/478
Biomedical and Life Sciences
Biomedicine
Cancer Research
Comment
Infectious Diseases
Liver diseases
Metabolic Diseases
Molecular Medicine
Neurosciences
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.
ISSN:1078-8956
1546-170X
1546-170X
DOI:10.1038/s41591-024-02958-z